Association of TP53 rs1042522 with cervical cancer in the sub‐Saharan African population: a meta‐analysis

Abstract

objective TP53 plays a crucial role in preventing cancer development. Previous studies in sub-Saharan Africa (SSA) reported inconclusive findings for the association of the TP53 rs1042522 C > G variant with cervical cancer. We therefore performed a meta-analysis to summarise this association in the SSA population.methods Online databases were searched to identify suitable articles according to the PRISMA guidelines. We included studies published in English or French that provided the sample sizes and genotype counts for both cases and controls and evaluated the association between TP53 rs1042522 and cervical cancer in the SSA population. A fixed-effect model was used to calculate the pooled odds ratio (OR) and 95% confidence intervals (95% CIs).results A total of 699 cervical cancer cases and 1008 controls from eight studies in SSA were included in this meta-analysis. Women harbouring the variant G allele of the TP53 rs1042522 were at increased risk of cervical cancer in allelic (G vs. C; OR = 1.30, 95% Cl = 1.12-1.50), homozygous (GG vs. CC; OR = 1.62, 95% CI = 1.20-2.19) and recessive (GG vs. CG + GG; OR = 1.74, 95% CI = 1.34-2.25) genetic models. However, the dominant genetic model (CG + GG vs. CC; OR = 1.20, 95% CI = 0.96-1.48) was not significantly associated with cervical cancer.conclusions Our meta-analysis revealed that harbouring variant G allele of TP53 rs1042522 is associated with cervical cancer risk in the SSA population.keywords cervical cancer, TP53 rs1042522, polymorphism, sub-Saharan Africa, meta-analysis Sustainable Development Goals (SDGs): SDG 3 (good health and well-being), SDG 17 (partnerships for the goals)

Haplotypes of single cancer driver genes and their local ancestry in a highly admixed long-lived population of Northeast Brazil

“…, 2019 ; Pouladi et al , 2019 ; Elshazli et al. , 2020 ; Kamiza et al, 2020 ; Liu et al , 2020 ) CTG (15.0%) 1 28.29 0.258 0.93-1.0 ACG (14.6%) -0.97 25.27 0.258 0.89-1.0 ATG (11.0%) -0.95 72.4 0.606 0.9-0.98 HNF1B CGG (49.3%) rs7501939 rs11651052 rs11658063 -0.95 72.4 0.606 0.9-0.98 rs7501939 ( Setiawan et al , 2012 ; Chornokur, 2013a ; Nikolić et al, 2014 ; Kristiansen et al. , 2015 ; Ríos-Tamayo et al , 2016 ; Oh et al, 2017a ; Tong et al., 2018 ) rs11651052 ( Painter et al , 2015 ).…”

“…The present study was based on 35 SNPs that can potentially modify the risk of cancer. A literature research revealed that only 10 of these 35 SNPs were described in studies of African or Afro-American populations ( Mechanic et al, 2007 ; Chornokur et al., 2013b ; Nikolić et al, 2014 ; Oh et al, 2017b ; Oussalah et al, 2017 ; Tong et al., 2018 ; Jones et al, 2019 ; Sagna et al, 2019 ; Song et al, 2019 ; Kamiza et al., 2020 ), suggesting that most association studies including these SNPs focused on European and Asian populations. The present results showed that a high number of individuals were homozygous for risk alleles with Native American and African ancestry that may modify the risk of cancer.…”

Associations of MDM2 rs2279744 and TP53 rs1042522 polymorphisms with cervical cancer risk: A meta-analysis and systematic review

“…Hence, our study set the OR value of the correlation between MDM2 rs2279744 polymorphism and cervical cancer as the reciprocal of 1.5 (i.e., 0.67). A review of the past literature indicated that the OR of the association between TP53 rs1042522 polymorphism and cervical cancer was 1.3 in the allele model (31). Consequently, the OR value of TP53 rs1042522 polymorphism and cervical cancer was set at 1.3.…”

The Genetic Changes of Hepatoblastoma

“…Aberrant expression and dysfunction of TP53 have been detected in various human tumor cases. The TP53 rs1042522 C>G polymorphism leads to an amino acid alteration (Arg to Pro) and therefore influences the susceptibility of various malignant tumors (101)(102)(103). Our research group conducted two studies to explore the association between TP53 rs1042522 C>G polymorphism and hepatoblastoma.…”